{"id":"NCT00408629","sponsor":"Abbott","briefTitle":"Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2006-12-07","resultsPosted":"2011-03-31","lastUpdate":"2011-05-03"},"enrollment":518,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"placebo","otherNames":[]}],"arms":[{"label":"adalimumab group","type":"EXPERIMENTAL"},{"label":"placebo group","type":"EXPERIMENTAL"}],"summary":"This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).","primaryOutcome":{"measure":"Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Adalimumab 160/80/40","deltaMin":16.5,"sd":null},{"arm":"Placebo","deltaMin":9.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.019"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":108,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","New Zealand","Norway","Poland","Portugal","Spain","Switzerland"]},"refs":{"pmids":["29380251","25041859","24067881","23173821"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":257},"commonTop":["Colitis ulcerative","Nasopharyngitis","Headache","Arthralgia","Abdominal pain"]}}